The government of South Korea will be improving subsidies to the country’s catheter users after the turn of the year, marking a breakthrough for Coloplast’s Continence Care business in the country.
Thousands of South Koreans suffering from disorders such as spinal cord injury, multiple sclerosis and Parkinson’s disease will be able to opt for better and more modern catheters next year. Public reimbursement rules in South Korea have been improved, and that is good news to Coloplast, as the company aims to outgrow the market in the Continence Care business area.
An estimated 25,000 users in South Korea who need help emptying their bladder are covered by the public reimbursement scheme in the country, and they will now be able to opt for modern catheters. According to Coloplast CEO Lars Rasmussen, the reimbursement will support the company’s growth opportunities in South Korea.
"This is good news for Coloplast in South Korea and for the users, whose everyday lives will be made easier with the benefits of modern catheters, enabling them to live the life they want to", says Coloplast CEO Lars Rasmussen.
Previously, South Korea only offered reimbursement to a limited group of users, but the improved access will allow all catheter users covered by the national health insurance access to better products.
Continence Care is Coloplast's second-largest business area, accounting for some 35% of consolidated revenue. Coloplast’s other business areas are Ostomy Care, Wound & Skin Care, and Urology Care. Last year, Coloplast generated revenue of DKK 14.7 billion.
Maria Lindeberg, Senior Media Relations Manager
Tel: + 45 49 11 30 95
Last updated on: 29/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.